Document is current
Any future updates will be listed below
-
Authors
Nie, Wei
Wang, Zhi-Jie
Zhang, Kai
Li, Bing
Cai, Yi-Ran
Wen, Feng-Cai
Zhang, Ding
Bai, Yue-Zong
Zhang, Xue-Yan
Wang, Shu-Yuan
Cheng, Lei
Zhong, Hua
Liu, Li
Wang, Jie
Han, Bao-Hui http://orcid.org/0000-0002-3950-3030
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (81601988)
Shanghai Chest Hospital Project of Collaborative Innovation (YJXT20190102)
nurture projects for basic research of Shanghai Chest Hospital (2021YNJCM02)
- License Information
-
More Information
Article History
Received: 9 January 2022
Accepted: 29 March 2022
First Online: 5 May 2022
Declarations
:
: This study was approved by the Ethics Committee of Shanghai Chest Hospital (Institutional review board No. IS2118), Wuhan Union Hospital (Institutional review board No. 2017-247), and National Cancer Center (Institutional review board No. NCC2018–092). Informed written consent was obtained from each subject or each subject’s guardian.
: Not applicable.
: Bao-Hui Han has consulted for AstraZeneca and Roche Pharmaceutical Company. He also received payment for speaking from AstraZeneca Pharmaceutical Company and Lily Pharmaceutical Company. Bing Li and Yi-Ran Cai are the employee of Burning Rock Biotech, Inc. Feng-Cai Wen, Ding Zhang and Yue-Zong Bai are the employee of 3D Medicines Inc. All remaining authors have declared no conflicts of interest.
